大株红景天注射液治疗晚期非小细胞肺癌患者的临床效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (60 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Sofren Injection in the treatment of patients with advanced nonsmall cell lung cancer(NSCLC).Methods A total of 120 patients with advanced NSCLC admitted to the Binzhou Medical University Hospital from January to December 2018 were selected as study subjects,and were divided into the control group and the treatment group by the random number table method,with 60 patients in each group.All patients were divided into control group and treatment group by the random number table method,with 60 patients in each group.The control group was given Compound Sophora Flavescens Injection and symptomatic treatment,and the treatment group was given Sofren Injection on this basis.The levels of serum tumor markers,traditional Chinese medicine symptom scores and immune function indexes before and after treatment were compared between the two groups.The short-term efficacy was compared between the two groups.Quality of life scores before and after treatment were compared between the two groups.Results The levels of carcinoembryonic antigen (CEA),cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 19-9(CA19-9),and neuron-specific enolase(NSE)in the two groups were lower than those before treatment,with statistically significant differences (P＜0.05).After treatment,CEA,CYFRA21-1,CA19-9 and NSE in the treatment group were all lower than those in the control group,with statistically significant differences (P＜0.05).The scores of traditional Chinese medicine symptoms of cough and expectoration of sputum,chest congestion and shortness of breath,abdominal distension and stupor,nausea and vomiting,and limb weakness in the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P＜0.05).The scores of traditional Chinese medicine symptoms of cough and expectoration of sputum,chest congestion and shortness of breath,abdominal distension and stupor,nausea and vomiting,and limb weakness in the treatment group were lower than those in the control group,with statistically significant differences(P＜0.05).The total effective rate and stability of the treatment group were higher than those of the control group,and the differences were statistically significant(P＜0.05).The total effective rate and stability of the treatment group were higher than those of the control group,and the difference was statistically significant(P＜0.05).After treatment,CD4+and CD4+/CD8+in the two groups were higher than those before treatment,and CD8+was lower than that before treatment,with statistically significant differences (P＜0.05).After treatment,CD4+and CD4+/CD8+in the treatment group were higher than those in the control group,and CD8+was lower than that in the control group,with statistically significant differences(P＜0.05).The scores of dyspnea,anorexia,cough,hemoptysis and pain in the treatment group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Sofren Injection can significantly alleviate traditional Chinese medicine symptoms of patients with advanced NSCLC,and significantly improve the clinical treatment effect of patients with intermediate and advanced lung cancer,it can improve the immune function,and improve the clinical symptoms.It is worthy of clinical application.

Key words： Advanced non-small cell lung cancer Sofren Injection Quality of life Serum tumor markers

Received: 31 March 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Xiao-long1 CHENG Wen-na1 ZHANGJing-yi2▲

Cite this article:

ZHOU Xiao-long1 CHENG Wen-na1 ZHANGJing-yi2▲. Clinical effect of Sofren Injection in the treatment of patients with advanced non-small cell lung cancer[J]. 中国当代医药, 2020, 27(24): 17-21转26.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I24/17

[1]	江琳，贾英杰.大株红景天注射液对非小细胞肺癌患者D-二聚体的影响及预后因素分析[J].亚太传统医药，2017，13（12）：151-154.
[2]	栗莉芳，王海英，闫翠芳，等.大株红景天注射液对非小细胞肺癌患者化疗后生活质量及不良反应的影响[J].临床合理用药杂志，2015，8（19）：54-55.
[3]	支修益，石远凯，于金明.中国原发性肺癌诊疗规范（2015年版）[J].中华肿瘤杂志，2015，37（1）：67-68.
[4]	石远凯，孙燕，于金明，等.中国晚期原发性肺癌诊治专家共识（2016年版）[J].中国肺癌杂志，2016，19（1）：7-21.
[5]	栗莉芳，王海英，闫翠芳，等.大株红景天注射液对非小细胞肺癌患者免疫功能的影响[J].临床合理用药杂志，2015，8（25）：30-31.
[6]	高佩.肺复康方联合埃克替尼治疗气阴两虚痰瘀毒结型中晚期非小细胞肺癌临床研究[D].长沙：湖南中医药大学，2016：17-18.
[7]	张素芳，郝爱芹，王建正.化疗联合参麦注射液对晚期非小细胞肺癌患者细胞免疫及肿瘤恶性程度的影响[J].世界中医药，2017，12（5）：136-140，144.
[8]	程小峰.大株红景天注射液应用于肺癌化疗患者的临床研究[D].福州：福建中医药大学，2013：11-12.
[9]	罗湘玉，杜春玲，黄平，等.大株红景天注射液防治周围型肺癌肺叶切除术后疲劳综合征的临床研究[J].中国医药导报，2016，13（26）：144-147.
[10]	和殿峰，蒋立峰.益肺消积方对晚期非小细胞肺癌患者血清肿瘤标志物及生活质量的影响[J].中医学报，2017，32（9）：1583-1585.
[11]	史博文，岳东升，孙冰生，等.治疗前血浆纤维蛋白原及D-二聚体水平联合预测晚期非小细胞肺癌患者预后[J].天津医药，2017，45（4）：46-50.
[12]	李发祥.阿帕替尼联合GP方案治疗晚期非小细胞肺癌的疗效及安全性[J].实用癌症杂志，2019，34（6）：952-955.
[13]	何小鹤.化瘀解毒法联合化疗治疗痰瘀互结型中晚期非小细胞肺癌的临床观察[D].郑州：河南中医药大学，2018：9-10.
[14]	孙亚华，徐红双，张延勇，等.自拟参麦养心汤联合磷酸肌酸对接受CAF化疗方案的乳腺癌患者氧自由基及心脏功能的影响[J].现代中西医结合杂志，2017，26（23）：2528-2531.
[15]	胡楠，刘琳，曾媛，等.血清癌胚抗原与肺癌关系的研究进展[J].癌症进展，2020，18（6）：547-548，602.
[16]	冯白昌.CYFRA21-1、NSE、CEA、CA125、CA19-9联合检测对肺癌的诊断意义[J].中国保健营养，2020，30（10）：81.
[17]	杨广山，陶宋词，徐媛媛.益气养阴解毒方联合化疗治疗中晚期非小细胞肺癌22例[J].安徽中医药大学学报，2016，35（4）：25-27.
[18]	邱芝琳，葛信国.益气养阴解毒方联合化疗治疗非小细胞肺癌临床研究[J].中医学报，2014，29（10）：1397-1399.